The use of cryptocurrency as a payment method in the growing gray-market peptide industry is becoming more common, according to a recent analysis by Chainalysis. The firm reported that off-label peptide sales have surpassed an annual run rate of $100 million, driven by online wellness trends and the search for cheaper alternatives. In the first quarter of 2026, sales reached $32 million, marking a 159% increase from $12 million in the previous quarter. This surge is linked to heightened public interest in peptides, which are essential building blocks for proteins used in health and fitness. The success of drugs like Ozempic and Wegovy has brought peptide-related products into mainstream discussions, even as many consumers seek unregulated options.
Chainalysis highlighted that traditional banks and card processors often block transactions involving prescription-grade compounds, leading vendors to adopt cryptocurrencies for seamless payments. The peptide trade operates as a gray market, with overseas suppliers, particularly Chinese chemical manufacturers, providing raw and unbranded products directly to buyers. These sellers frequently face restrictions in conventional banking, making crypto an attractive alternative. The analysis found that top vendors have become more organized in their use of crypto, with many accepting bitcoin and stablecoins. Larger vendors, however, show a clear preference for stablecoins.
Among suppliers receiving average deposits of $1,000 or more, stablecoins accounted for the majority of payments. This trend likely helps sellers avoid the volatility of bitcoin when processing larger orders. Chainalysis also compared the peptide market to other research-chemical networks that rely on crypto. Some suppliers connected to fentanyl precursor sales have reportedly expanded into peptides, as seen in the case of Shanghai Sigma Audley, which received $1 million in bitcoin and $3.59 million in stablecoins from such sales before moving into peptides.
Concerns about product safety are rising, as Chainalysis noted a significant drop in testing spend per buyer. While many peptide buyers previously paid for independent purity testing via Janoshik, a Czech company, the average testing expenditure has fallen by 88% to about $8 per buyer. Although Janoshik tests more products overall due to a larger buyer base, the decline per buyer raises red flags. The report emphasized that the peptide sector often attracts individuals with limited experience in both cryptocurrency and unregulated pharmaceuticals, amplifying risks related to product quality, payment traceability, and legal boundaries.